Clinical Trial: A Clinical Trial to Evaluate the Efficacy and Safety of Bevemipretide Ophthalmic Topical Solution in Subjects Who Have Dry Age-Related Macular Degeneration (Dry AMD)

U.S., Nov. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07927010) titled 'A Clinical Trial to Evaluate the Efficacy and Safety of Bevemipretide Ophthalmic Topical Solution in Subjects Who Have Dry Age-Related Macular Degeneration (Dry AMD)' on Nov. 03.

Brief Summary: Approximately 300 subjects with eligible dry AMD will be randomized to one of three groups (low dose Bevemipretide, high dose Bevemipretide, or vehicle) to receive daily ophthalmic solution administration for 48 weeks.

Study Start Date: Nov., 2026

Study Type: INTERVENTIONAL

Condition: Dry AMD Age-Related Macular Degeneration (AMD)

Intervention: DRUG: 1 % Bevemipretide

Low Dose 1% bevemipretide ophthalmic topical solution

DRUG: 2% Beve...